At close: December 16 at 4:00:00 PM EST
After hours: 7:59:27 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 3 |
| Avg. Estimate | -0.74 | -0.81 | -2.98 | -2.37 |
| Low Estimate | -0.92 | -0.94 | -3.3 | -3.24 |
| High Estimate | -0.53 | -0.67 | -2.57 | -1.52 |
| Year Ago EPS | -1.1 | -0.98 | -3.86 | -2.98 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 5 | 9 | 9 |
| Avg. Estimate | 133.33k | 160k | 9.07M | 17.84M |
| Low Estimate | -- | -- | -- | 4.09M |
| High Estimate | 1.2M | 800k | 11.6M | 56.95M |
| Year Ago Sales | -- | -- | -- | 9.07M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 96.80% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.76 | -0.87 | -1.06 | -0.82 |
| EPS Actual | -1.1 | -0.98 | -0.61 | -0.88 |
| Difference | -0.34 | -0.11 | 0.45 | -0.06 |
| Surprise % | -44.74% | -13.08% | 42.59% | -7.32% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.74 | -0.81 | -2.98 | -2.37 |
| 7 Days Ago | -0.73 | -0.73 | -3.71 | -2.73 |
| 30 Days Ago | -0.69 | -0.73 | -3.35 | -2.73 |
| 60 Days Ago | -0.69 | -0.73 | -3.35 | -2.73 |
| 90 Days Ago | -0.71 | -0.73 | -3.35 | -2.32 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 2 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | 2 | 1 | -- | 2 |
| Down Last 30 Days | 1 | 1 | -- | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| VSTM | 33.03% | 17.86% | 22.88% | 20.38% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | Truist Securities: Buy to Buy | 8/13/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/12/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 8/9/2024 |
| Maintains | B. Riley Securities: Buy to Buy | 7/24/2024 |
| Maintains | Truist Securities: Buy to Buy | 7/8/2024 |
| Maintains | Alliance Global Partners: Buy to Buy | 5/29/2024 |
Related Tickers
RIGL Rigel Pharmaceuticals, Inc.
19.14
+1.22%
KPTI Karyopharm Therapeutics Inc.
0.6700
-4.29%
TCRX TScan Therapeutics, Inc.
3.0100
+5.61%
VOR Vor Biopharma Inc.
1.0200
+2.91%
VNDA Vanda Pharmaceuticals Inc.
4.6300
+0.43%
GALT Galectin Therapeutics Inc.
2.3100
+9.48%
EWTX Edgewise Therapeutics, Inc.
32.69
+18.36%
ADCT ADC Therapeutics SA
2.0000
+5.82%
FATE Fate Therapeutics, Inc.
2.0000
+9.29%
MRSN Mersana Therapeutics, Inc.
2.0700
-3.72%